Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Lutathera og ASTX727 i nevroendokrine svulster (LANTana)

11. november 2026 oppdatert av: Imperial College London

Den epigenetiske modifikasjonen av somatostatinreseptor-2 for å forbedre terapeutisk resultat med Lutathera hos pasienter med metastatiske nevroendokrine svulster.

Patients entered into the study will receive ASTX727 orally for 5 days, prior to receiving Lutathera treatment on Day 8, to determine whether pre-treatment with ASTX727 results in re-expression of somatostatin receptor-2 in patients with metastatic neuroendocrine tumours. The study will use [68Ga]-DOTA-TATE PET to image epigenetic modification of the receptor locus.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Patients with neuroendocrine tumours (NET) who are found to be eligible will receive up to 4 doses of Lutathera on this trial. All participants will receive ASTX727 orally (cedazuridine 100mg + 35mg decitabine) Days 0-5 prior to receiving Lutathera Day 8 +/- 2days. Each cycle will be repeated every 2 months for 4 cycles unless unacceptable toxicity, progression of disease or withdrawal of patients' consent. Restaging will occur after 2 cycles of Lutathera and at the end of treatment. Patients will be followed 3 monthly until disease progression, death or withdrawal of patients' consent.

Studietype

Intervensjonell

Registrering (Antatt)

37

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • London, City of
      • London, London, City of, Storbritannia, W12 0HS
        • Rekruttering
        • Hammersmith Hospital
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 99 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Be willing and able to provide written informed consent for the trial.

  2. Be aged 18 or over at the day of signing consent

  3. Histologic or cytologic confirmed diagnosis of neuroendocrine tumour

  4. Have archival tissue block available or willing to have fresh tissue biopsy if blocks not available

  5. Have disease that can be readily biopsied by ultrasound guidance (n=5)

  6. Ki67 < 55% (only patients with well differentiated grade 1-3 NETs will be included in the study as patients with poorly differentiated grade 3 NETs have a prognosis of less than 6 months)

  7. Progression or intolerance to first line therapy including somatostatin analogues

  8. ECOG Performance status 0 - 2

  9. No tumoural uptake on [68Ga]-DOTA-TATE or uptake less than background liver

  10. Measurable disease based on RECIST 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions

  11. Adequate organ function as outlined in the protocol

  12. Women of childbearing potential must be willing to use a highly effective method of contraception as outlined in the protocol for the course of the study through 6 months after the last dose of Investigational Medicinal Product (IMP).

    Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjects

  13. Sexually active males must agree to use an adequate method of contraception as outlined in the protocol starting with the first dose of IMP through 6 months after the last dose of study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject

    Expansion Cohort (n=10 participants):

  14. <50% disease occupation of liver

Exclusion Criteria:

  1. Previous treatment with either study medication and/or known hypersensitivity to the study medication
  2. Serious concurrent medical illness, including serious active infection
  3. History of organ transplant
  4. Has a known history of Human Immunodeficiency Virus (HIV). Note: No HIV testing is required unless mandated by local health authority.
  5. Has a known history of active Bacillus Tuberculosis (TB).
  6. Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.
  7. Bleeding or thrombotic disorders or subjects at risk for severe haemorrhage
  8. Is currently participating and receiving therapy or has participated or is participating in a study of an IMP or used an investigational device within 4 weeks of the first dose of IMP.
  9. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
  10. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating Principal Investigator (PI).
  11. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  12. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through to 6 months after the last dose of IMP.
  13. Has received a live vaccine within 30 days of first dose of ASTX727 administration. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.
  14. Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease and stereotactic radiotherapy to the CNS
  15. Other clinically significant co-morbidities that could compromise the subject's participating in the study

Expansion Cohort (n=10 participants):

15. > 2 lines of previous therapy, excluding somatostatin analogues

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Behandling

Cedazuridine 100mg + 35mg decitabine

Peptide receptor radionuclide therapy (PRRT)

Andre navn:
  • lutetium Lu 177 dotatat
Annen: Expansion Cohort

Cedazuridine 100mg + 35mg decitabine

Peptide receptor radionuclide therapy (PRRT)

Andre navn:
  • lutetium Lu 177 dotatat

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
To determine whether pre-treatment with ASTX727 results in re-expression of SSTR2 in patients with metastatic NETs, using [68Ga]-DOTA-TATE to image epigenetic modification of the SSTR2 locus allowing subsequent treatment with Lutathera
Tidsramme: Through study completion, an average of 1 year

This outcome will be assessed using a specific PET scan

Through study completion, an average of 1 year

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
To assess tolerability of combination therapy
Tidsramme: Through study completion, an average of 1 year

This outcome will be assessed using CTCAE v5.0

Through study completion, an average of 1 year
To assess response to treatment using conventional imaging
Tidsramme: Through study completion, an average of 1 year

This outcome will be assessed using standard of care CT scans

Through study completion, an average of 1 year
To assess patients quality of life during treatment
Tidsramme: Through study completion, an average of 1 year

This will be assessed using standardised quality of life questionnaires, which will be given to the patients

Through study completion, an average of 1 year
To assess progression free survival
Tidsramme: Through study completion, an average of 1 year

This will be the time until patients show progressive disease on their routine CT scans

Through study completion, an average of 1 year

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Rohini Sharma, Professor, Imperial College London

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

25. april 2022

Primær fullføring (Antatt)

30. mai 2027

Studiet fullført (Antatt)

30. januar 2030

Datoer for studieregistrering

Først innsendt

3. desember 2021

Først innsendt som oppfylte QC-kriteriene

16. desember 2021

Først lagt ut (Faktiske)

5. januar 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

12. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

11. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • RS - IC03
  • 21HH6544 (Annen identifikator: Imperial College London)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .